Creel C J, Lovich M A, Edelman E R
Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Circ Res. 2000 Apr 28;86(8):879-84. doi: 10.1161/01.res.86.8.879.
Successful implementation of local arterial drug delivery requires transmural distribution of drug. The physicochemical properties of the applied compound, which govern its transport and tissue binding, become as important as the mode of delivery. Hydrophilic compounds distribute freely but are cleared rapidly. Hydrophobic drugs, insoluble in aqueous solutions, bind to fixed tissue elements, potentially prolonging tissue residence and biological effect. Paclitaxel is such a hydrophobic compound, with tremendous therapeutic potential against proliferative vascular disease. We hypothesized that the recent favorable preclinical data with this compound may derive in part from preferential tissue binding as a result of unique physicochemical properties. The arterial transport of paclitaxel was quantified through application ex vivo and measurement of the subsequent transmural distribution. Arterial paclitaxel deposition at equilibrium varied across the arterial wall and was everywhere greater in concentration than in the applied drug source. Permeation into the wall increased with time, from 15 minutes to 4 hours, and varied with the origin of delivery. In contrast to hydrophilic compounds, the concentration in tissue exceeds the applied concentration and the rate of transport was markedly slower. Furthermore, endovascular and perivascular paclitaxel application led to markedly differential deposition across the blood vessel wall. These data suggest that paclitaxel interacts with arterial tissue elements as it moves under the forces of diffusion and convection and can establish substantial partitioning and spatial gradients across the tissue. The complexity of paclitaxel pharmacokinetics requires in-depth investigation if this drug is to reach its full clinical potential in proliferative vascular diseases.
局部动脉药物递送的成功实施需要药物的透壁分布。所应用化合物的物理化学性质决定其转运和组织结合,与递送方式同样重要。亲水性化合物可自由分布但清除迅速。疏水性药物不溶于水溶液,与固定的组织成分结合,可能延长组织驻留时间和生物效应。紫杉醇就是这样一种疏水性化合物,对增殖性血管疾病具有巨大的治疗潜力。我们推测,该化合物近期良好的临床前数据可能部分源于其独特物理化学性质导致的优先组织结合。通过体外应用和随后透壁分布的测量对紫杉醇的动脉转运进行了量化。平衡时动脉壁上的紫杉醇沉积在整个动脉壁上各不相同,且各处浓度均高于应用药物源中的浓度。从15分钟到4小时,向壁内的渗透随时间增加,并因递送部位而异。与亲水性化合物不同,组织中的浓度超过应用浓度,且转运速率明显较慢。此外,血管内和血管周围应用紫杉醇导致血管壁上的沉积明显不同。这些数据表明,紫杉醇在扩散和对流力作用下移动时与动脉组织成分相互作用,并可在组织中建立大量的分配和空间梯度。如果该药物要在增殖性血管疾病中充分发挥其临床潜力,紫杉醇药代动力学的复杂性需要深入研究。